Cabozantinib Response in a Patient With NSCLC Harboring Both MET Exon 14 Skipping Mutation and Secondary RET Fusion: A Case Report by Carlos Torrado, MD, Jamie Feng, MD, FRCPC, Elizabeth Faour, MD, FRCPC, Natasha B. Leighl, MD, MMSc, FRCPC, FASCO

Get full text

The Perceived Value of Liquid Biopsy: Results From a Canadian Validation Study of Circulating Tumor DNA T790M Testing—Patient’s Willingness-to-Pay: A Brief Report by Kaitlin H. Chen, BSc, Tristan A. Barnes, MD, BS, Janessa Laskin, MD, Parneet Cheema, MD, MBiotech, Geoffrey Liu, MD, MS, Mussawar Iqbal, MD, Jeffrey Rothenstein, MD, Ronald Burkes, MD, Ming-Sound Tsao, MD, Natasha B. Leighl, MD, MMSc

Get full text

Automating Access to Real-World Evidence by Marie-Pier Gauthier, MD, Jennifer H. Law, MSc, Lisa W. Le, MSc, Janice J.N. Li, BSc, Sajda Zahir, Sharon Nirmalakumar, BSc, Mike Sung, MD, Christopher Pettengell, BMBCh, Steven Aviv, BBusSc, Ryan Chu, MD, Adrian Sacher, MD, MSc, Geoffrey Liu, MD, MSc, Penelope Bradbury, MBChB, Frances A. Shepherd, MD, Natasha B. Leighl, MD, MMSc, FRCPC, FASCO

Get full text

Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With MET Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential Therapies by Sally C.M. Lau, MD, MPH, Kirstin Perdrizet, MD, Andrea S. Fung, MD, PhD, Danilo Giffoni M.M. Mata, MD, Jessica Weiss, PhD, Nick Holzapfel, MD, Geoffrey Liu, MD, Penelope A. Bradbury, MD, Frances A. Shepherd, MD, Adrian G. Sacher, MD, MMSc, Harriet Feilotter, MD, Brandon Sheffield, MD, David Hwang, MD, Ming Sound Tsao, MD, Susanna Cheng, MD, Parneet Cheema, MD, Natasha B. Leighl, MD, MMSc

Get full text